Analytical Data
-
Gene name
CHRM1
- Application
-
Alternative Names
CHR-M1; HM1; M1; M-AChRM1; Muscarinic Acetylcholine Receptor M1
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P08482
-
Expression Region
Arg210~Ala363
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHRM1, or cholinergic receptor muscarinic 1, is a pivotal protein in the muscarinic acetylcholine receptor family, which plays a crucial role in various physiological processes including neurotransmission, cognition, and muscle contraction. Research on CHRM1 has intensified due to its implication in various neurological disorders such as Alzheimer's disease, schizophrenia, and depression. The exploration of CHRM1 recombinant proteins has become essential for understanding its structural properties and functional mechanisms. By producing CHRM1 as a recombinant protein, researchers aim to analyze its interactions with ligands and downstream signaling pathways, thereby elucidating its role in health and disease. Furthermore, the study of CHRM1 can facilitate the development of targeted therapeutics that modulate its activity, potentially leading to novel treatments for conditions linked to cholinergic dysfunction. Overall, the investigation of CHRM1 recombinant proteins not only enhances our understanding of cholinergic signaling but also paves the way for innovative approaches in the management of neurological disorders.
